Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance Olaparib in Advanced NSCLC (PIPSeN)
NCT02679963Phase 2Terminated
- Sponsor
- Gustave Roussy
- Start
- Feb 2016
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of olaparib in non-small cell lung cancer (NSCLC), sponsored by Gustave Roussy. Started Feb 2016; status: terminated.
02
Drugs
olaparib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02679963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02679963.